A massive genetic study involving almost 800,000 participants has uncovered genetic factors that contribute to the use of sleep medications, shedding new light on the intricate relationship between sleep problems and psychiatric conditions.

We teamed-up with experts on data visualisation from Aalto University to co-create a new accessible and engaging communication resource. Scroll through the website to learn about the FinnGen project, its goals, processes and its impact in Finland and around the world. Don't miss out – explore now and expand your horizons!

Results based on the FinnGen data are presented in almost 40 talks or posters during the 2023 Annual Meeting of the American Society of Human Genetics (ASHG) in Washington DC, November 1-5. Come and meet our researchers!

The FinnGen research consortium has successfully collected and generated genomic data from 500,000 individuals. Now, the project will continue its search for genetic clues to disease progression and explore the biological mechanism of the genetic signals uncovered in the first stages of the project.

FinnGen has met its target of collecting 500,000 participants on schedule. We want to thank each and every Finnish biobank sample donor for making medical research possible and the biobanks for their excellent cooperation over the past six years!

We are happy to announce that the FinnGen data freeze 9 results and summary statistics are now publicly available!

New results from the FinnGen research consortium demonstrate the undeniable benefits of Finnish health research environment for genomic research. Among the wealth of novel genetic discoveries are previously unknown genetic risk factors for many debilitating diseases. These findings have potential to facilitate the development of new therapies.

A large-scale biobank-based study performed in Finland has discovered several new disease genes as well as new insights on how known genetic factors affect disease. The study highlights an underappreciated complexity in the dosage effects of genetic variants.

A study led by the University of Helsinki has identified more than 300 gene regions associated with the use of cholesterol drugs, antihypertensives or antidiabetic drugs. Genomic regions linked to drug use also helped identify new cardiovascular disease risk genes.

The FinnGen research team has identified 27 hereditary risk factors for otosclerosis, a disease that disrupts the function of bones in the middle ear and causes hearing loss. Some of the identified genetic variants are specific to the Finnish population.